Key points are not available for this paper at this time.
To examine the association between the use of incretin-based drugs glucagon-like peptide-1 receptor agonists (GLP-1RAs), dipeptidyl peptidase-4 inhibitors (DPP-4Is) and the risk of cholangiocarcinoma (CCA) in the United States.
Krishnan et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: